Dongkoo Bio & Pharma, which has established a strong presence in the prescription drug sector, is accelerating its efforts to enter the global cosmetics and skin booster markets.
On April 25, Dongkoo Bio & Pharma announced that it had signed an exclusive supply agreement worth approximately 10 billion KRW with Chung Tai Energy, a comprehensive conglomerate in Taiwan, for its cosmeceutical skincare brand Cell Bloom.
This strategic move is aimed at strengthening the global market position of Dongkoo Bio & Pharma's flagship brand Cell Bloom, and is expected to further enhance its competitiveness in Taiwan's premium cosmetics market.
Chung Tai Energy, Dongkoo Bio & Pharma's local partner, is one of Taiwan's leading companies, having grown based on eco-friendly energy and resource recycling. Recently, it has expanded its portfolio into diverse sectors including renewable energy, bio, healthcare, and cosmetics, and is accelerating its global expansion through the establishment of a U.S. subsidiary.
The entry of Cell Bloom into the Taiwanese market is drawing attention as a synergy case that combines Chung Tai's local distribution capabilities with Dongkoo Bio & Pharma's product strength and brand value. Cell Bloom recently obtained official product approval from Taiwan’s Ministry of Health and Welfare (MHW), certifying the product’s quality, safety, and innovation. Dongkoo Bio & Pharma has established a global response system based on a quality management system that meets the requirements of both global and local regulatory agencies.
After Taiwan’s Ministry of Health and Welfare officially allowed human-derived exosomes as cosmetic ingredients in March last year, Dongkoo Bio & Pharma launched new ampoule products containing human- and plant-derived stem cell exosomes exclusively for export to Taiwan. The exclusive contract is a strategic alliance formed in this context and is attracting significant attention in the market.
Dongkoo Bio & Pharma is actively targeting the global market with next-generation filler products by securing the largest shareholder position in Areum Medics through new share acquisition. The company plans to further expand its global influence in the cosmetics and skin booster sectors through continued investment in research and development (R&D) and global collaborations.
Cho Yongjun, CEO of Dongkoo Bio & Pharma, stated, "The exclusive contract in Taiwan is more than just a distribution partnership; it will serve as a strategic milestone for the global expansion of Cell Bloom," adding, "We will accelerate our efforts to enter the global market, focusing on Cell Bloom and high-performance skin booster products."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
